COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Straumann Group outlines its mid-term growth strategy to accelerate market shares, strengthen profitability and increase cash generation
Straumann Group presented its mid-term growth strategy at Capital Markets Day, focusing on accelerating market shares, profitability, and cash generation through digital innovation and ecosystem -
COMMUNIQUÉ DE PRESSE
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination
Relief Therapeutics and NeuroX reveal joint presentation and financial outlook in anticipation of business combination. Financial guidance includes revenue projections and EBITDA margin targets -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
Dupixent de Sanofi et Regeneron approuvé dans l'UE pour l'urticaire chronique spontanée. Impact positif sur les patients avec symptômes malgré antihistaminiques. Nouvelle option thérapeutique basée sur inhibition IL4 et IL13 -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron receive EU approval for Dupixent as targeted medicine for chronic spontaneous urticaria, significantly reducing itch and hives compared to placebo -
-
